|
|
Office Locations:
|
985 Old Eagle School Road, Suite 511
Wayne, PA 19087
Phone: 610-567-1000
Fax: 610-567-1039
| |
|
|
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
SR One was GlaxoSmithKline's (GSK) independent corporate healthcare venture capital fund but recently spun out once closing its first independent fund. SR One is a leading trans-Atlantic biotech venture capital firm. SR One invests globally in emerging life science companies focused on drug discovery, development or delivery that have the potential to make products that can have a dramatic benefit to patients. SR One is interested in companies with products that are in preclinical development through clinical proof-of-concept. Overall, the firm looks for investments that can provide attractive financial returns and significant strategic value. The firm's current portfolio includes more than 30 private and public companies and since its founding in 1985, SR One has invested over $680MM in the biotech space.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
